Compare Dover Corp (DOV) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs BIO-TECHNE Corp — how do they compare? Dover Corp trades at $208.79 (market cap $28.30B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Dover Corp is far larger — about 2.5× BIO-TECHNE Corp's market cap, and Dover Corp pays the higher dividend (0.99%). Which is the better fit depends on your goals.
| DOV | TECH | |
|---|---|---|
Market Cap | $28.30B | $11.24B |
Sector | Industrials | Health |
52-Week High | $233.31 | $72.29 |
52-Week Low | $161.16 | $43.31 |
Enterprise Value | $29.80B | $11.32B |
Dividend Yield | 0.99% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $211.13, up 0.14% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat expectations with EPS of $2.74, and the company raised its full-year guidance. A dividend increase to $0.525 per share and the acquisition of Cloeren highlight positive corporate actions. Valuation ratios include a P/E of 25.53 and net income margin of 13.48%, reflecting solid profitability.
The outlook for DOV is positive, driven by earnings momentum, raised guidance, and strategic acquisitions. Risks include exposure to manufacturing cycles and macroeconomic volatility. With 19 buy ratings and a consensus price target of $232.33, Wall Street sees upside potential, though investors should monitor execution on growth initiatives and sector headwinds.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
